Physician profile
Anthony Hudson
NPI 1144595455
$3,569.43
in general payments reported to CMS, 2019-2025
24 companies · $732 in 2025
The $732 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $307 · 2021: $514 · 2022: $371 · 2023: $557 · 2024: $535 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $946.93 | 2019-2024 | Jornay Pm |
| Corium, LLC | $421.10 | 2021-2025 | Azstarys |
| Tris Pharma INC | $379.46 | 2019-2025 | Onyda Xr |
| Supernus Pharmaceuticals, INC. | $370.56 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $253.27 | 2020-2025 | Penmenvy, Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $224.52 | 2019-2024 | Vaxelis, Gardasil 9, Gardasil |
| Pfizer INC. | $188.85 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $144.44 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $91.86 | 2019-2021 | |
| Adlon Therapeutics L.P. | $80.48 | 2019-2021 | |
| Phadia US INC. | $75.00 | 2019-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $74.12 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.81 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $56.68 | 2019-2025 | Relexxii |
| Cranial Technologies, INC | $31.79 | 2024 | Doc Band |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27.15 | 2024 | Dupixent |
| Genentech USA, INC. | $24.62 | 2019-2020 | |
| Seqirus USA INC | $21.63 | 2025 | Flucelvax |
| Ars Pharmaceuticals Operations, INC. | $17.67 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $14.69 | 2025 | Zoryve |
| Cipher Pharmaceuticals US LLC | $14.36 | 2025 | Spinosad, Natroba |
| Azurity Pharmaceuticals, INC. | $14.09 | 2025 | Alvesco |
| Sanofi Pasteur INC. | $13.28 | 2023 | |
| Novartis Pharmaceuticals Corporation | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.